Vertex- Scottish govt. sign cystic fibrosis treatment access contract
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex- Scottish govt. sign cystic fibrosis treatment access contract

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines.

Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligible to have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor subsequently after signing an agreement for access.

Ludovic Fenaux, Senior VP, Vertex International, reportedly stated that the company would like to appreciate the Scottish authorities for their partnership and the flexible and collaborative way which helped both of the entities have worked together to figure out an access solution. It means that about 400 eligible patients suffering from cystic fibrosis in Scotland will now be able to have access to SYMKEVI or ORKAMBI, he further added.

Apparently, as part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. This data will further support any future submissions to the Scottish Medicines Consortium (SMC).

Reportedly, Vertex cystic fibrosis medicines have been reimbursed in 17 countries around the world. These 17 countries include Australia, Austria, Denmark, Germany, Italy, the Republic of Ireland, the Netherlands, the U.S. and Sweden.

According to reliable sources, around 900 people in Scotland are suffering from CF. In the United Kingdom, 32 years is the median age of death of people suffering from CF. NHS Scotland has estimated that one in 24 Scots have a CFTR mutation. If this mutation is carried by both parents then it may lead to a baby being born with CF.

For the record, Vertex is a multinational biotechnology firm which invests in innovative initiatives to develop medicines for patients suffering from serious disorders. The company owns three approved medicines which can treat the primary cause of cystic fibrosis (CF).  Cystic fibrosis is a rare and life-threatening genetic disorder. There are several ongoing clinical and research programs going on to develop efficient treatment of CF.

Source Credit:

https://www.businesswire.com/news/home/20190912005349/en/Vertex-Announces-New-Access-Agreement-Scottish-Government

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Cryptocurrency platform Binance acquires dApp startup DappReview
Cryptocurrency platform Binance acquires dApp startup DappReview
By Mateen Dalal

Binance, a renowned cryptocurrency exchange platform where more than 100 cryptocurrencies are traded, reportedly announced the acquisition of DappReview, an evaluation platform offering advertising and data-driven research services to blockchain-base...

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
By Mateen Dalal

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Ap...

Prescient expands PTX-200 trial after it eradicates cancer completely
Prescient expands PTX-200 trial after it eradicates cancer completely
By Mateen Dalal

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemia) after the disease was complet...